BioCentury
ARTICLE | Product Development

FDA green-lights more than 70 COVID-19 trials via treatment acceleration program

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

April 21, 2020 12:01 AM UTC

FDA’s Coronavirus Treatment Acceleration Program has cleared the start of 72 therapeutics trials, with another 211 development programs being planned, the agency said Monday.

CTAP launched on March 31 and has received 950 inquiries and proposals related to COVID-19 drug development as of April 16...